Total Payments
$1,153
2024 Payments
$38.97
Companies
10
Transactions
14
Medicare Patients
4,489
Medicare Billing
$808,011
Payment Breakdown by Category
Food & Beverage$864.51 (75.0%)
Education$288.71 (25.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $864.51 | 10 | 75.0% |
| Education | $288.71 | 4 | 25.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $382.63 | 4 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $124.84 | 1 | $0 (2018) |
| Merck Sharp & Dohme LLC | $116.12 | 1 | $0 (2022) |
| Paratek Pharmaceuticals, Inc. | $115.62 | 1 | $0 (2023) |
| Insmed, Inc. | $111.18 | 1 | $0 (2023) |
| ABBVIE INC. | $107.97 | 1 | $0 (2022) |
| The Medicines Company | $89.09 | 1 | $0 (2017) |
| R-Pharm US LLC | $46.04 | 2 | $0 (2017) |
| MIMEDX Group, Inc. | $38.97 | 1 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $20.76 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38.97 | 1 | MIMEDX Group, Inc. ($38.97) |
| 2023 | $247.56 | 3 | Paratek Pharmaceuticals, Inc. ($115.62) |
| 2022 | $224.09 | 2 | Merck Sharp & Dohme LLC ($116.12) |
| 2018 | $338.52 | 3 | Astellas Pharma US Inc ($213.68) |
| 2017 | $304.08 | 5 | Astellas Pharma US Inc ($168.95) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/02/2024 | MIMEDX Group, Inc. | — | Food and Beverage | In-kind items and services | $38.97 | General |
| 09/19/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $111.18 | General |
| Category: Respiratory | ||||||
| 08/24/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $115.62 | General |
| Category: ANTIBIOTIC | ||||||
| 03/17/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Education | In-kind items and services | $20.76 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/27/2022 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $116.12 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/31/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $107.97 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/28/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 05/25/2018 | Regeneron Healthcare Solutions, Inc. | PRALUENT ALIROCUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $124.84 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 03/20/2018 | Astellas Pharma US Inc | CRESEMBA (Drug) | Food and Beverage | In-kind items and services | $114.68 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 11/07/2017 | The Medicines Company | VABOMERE (Drug) | Food and Beverage | In-kind items and services | $89.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/07/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 09/07/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $69.95 | General |
| 07/13/2017 | R-Pharm US LLC | Ixempra (Drug) | Food and Beverage | Cash or cash equivalent | $25.53 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2017 | R-Pharm US LLC | Ixempra (Drug) | Food and Beverage | Cash or cash equivalent | $20.51 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 941 | 1,956 | $603,762 | $153,720 |
| 2022 | 5 | 1,114 | 2,292 | $739,928 | $182,961 |
| 2021 | 5 | 1,124 | 2,534 | $786,097 | $203,579 |
| 2020 | 6 | 1,310 | 3,428 | $997,376 | $267,751 |
Total Patients
4,489
Total Services
10,210
Medicare Billing
$808,011
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 249 | 581 | $182,004 | $51,233 | 28.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 281 | 855 | $187,348 | $49,992 | 26.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 256 | 279 | $169,961 | $35,375 | 20.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 95 | 179 | $39,953 | $11,499 | 28.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 48 | 50 | $20,600 | $4,755 | 23.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,897 | $865.80 | 22.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 361 | 409 | $249,155 | $60,901 | 24.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 296 | 728 | $228,053 | $56,321 | 24.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 326 | 968 | $212,108 | $51,703 | 24.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 85 | 140 | $31,248 | $9,277 | 29.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 46 | 47 | $19,364 | $4,758 | 24.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 396 | 1,286 | $281,788 | $72,899 | 25.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 291 | 761 | $238,391 | $61,938 | 26.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 335 | 377 | $229,661 | $59,331 | 25.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 60 | 62 | $25,543 | $6,645 | 26.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 42 | 48 | $10,714 | $2,766 | 25.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 484 | 2,012 | $440,869 | $117,887 | 26.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 315 | 850 | $266,271 | $72,217 | 27.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 339 | 373 | $227,224 | $60,883 | 26.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 115 | 125 | $51,499 | $13,956 | 27.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 32 | 33 | $7,366 | $1,730 | 23.5% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 25 | 35 | $4,148 | $1,078 | 26.0% |
About Dr. Mallikarjuna Mukka, M.D
Dr. Mallikarjuna Mukka, M.D is a Infectious Disease healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487608923.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mallikarjuna Mukka, M.D has received a total of $1,153 in payments from pharmaceutical and medical device companies, with $38.97 received in 2024. These payments were reported across 14 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($864.51).
As a Medicare-enrolled provider, Mukka has provided services to 4,489 Medicare beneficiaries, totaling 10,210 services with total Medicare billing of $808,011. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Internal Medicine
- Location Fort Worth, TX
- Active Since 05/20/2006
- Last Updated 07/23/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1487608923
Products in Payments
- PRALUENT ALIROCUMAB INJECTION (Biological) $124.84
- RECARBRIO (Drug) $116.12
- NUZYRA (Drug) $115.62
- CRESEMBA (Drug) $114.68
- Arikayce (Drug) $111.18
- DALVANCE (Drug) $107.97
- VABOMERE (Drug) $89.09
- Ixempra (Drug) $46.04
- REBYOTA (Biological) $20.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Fort Worth
Dr. Cedric Spak, Md, MD
Infectious Disease — Payments: $450,470
Infectious Disease $450,470
Cheryl Mcdonald, M.d, M.D
Infectious Disease — Payments: $214,900
Infectious Disease $214,900
Daniel Barbaro, M.d, M.D
Infectious Disease — Payments: $74,179
Infectious Disease $74,179
Mark Hupert, M.d, M.D
Infectious Disease — Payments: $10,107
Infectious Disease $10,107
Dr. Steven Sotman, M.d, M.D
Infectious Disease — Payments: $4,353
Infectious Disease $4,353
Dr. Vitaly Golub, Md, MD
Infectious Disease — Payments: $4,211
Infectious Disease $4,211